- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04279197
Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu
Efficacy and Safety of Fuzheng Huayu Tablets in Post-COVID-19 Patients With Pulmonary Inflammation and Fibrosis : A Multicenter Double-blind Randomized Controlled Trial
Study Overview
Status
Conditions
Detailed Description
The patients with COVID-19 could suffered from the pulmonary dysfunction and/or fibrosis the recovery period, but there are no certain drugs or treatment to cope with this situation. Our previous studies indicated that Fuzheng Huayu tablets (FZHY) could regress the lung fibrosis induced by bleomycin in animals, and improve the pulmonary function in the patients with chronic obstructive pulmonary disease. Now we design this trial to carry out the clinical study in order to evaluate the effects of Fuzheng Huayu tablets on pulmonary fibrosis and/or pulmonary function injury in the recovery period of COVID-19 and expect to improve the prognosis.
This is a randomized, double-blind, multicenter, placebo-controlled clinical trial.It enrolls 142 patients who had been diagnosed with COVID-19, but currently they are negative for viral testing and have developed pulmonary fibrosis or pulmonary dysfunction. They are randomly assigned into Placebo group and FZHY group. All patients are given usual treatment such as respiratory function rehabilitation training and vitamin C. The FZHY group is given Fuzheng Huayu tablets, and the control group is given placebo. Each patient will be observed for 24 weeks and followed up for 8 weeks. The primary outcomes for the trial are the improvement proportion of pulmonary fibrosis judged by HRCT score and the improvement of lung function(FVC,FEV1,FVC/FEV1). Secondary outcomes include six-minute walk distance, improvement proportion of pulmonary inflammation, improvement proportion of clinical symptoms , quality of Life-BREF (QOL-BREF) Score, patient health questionnaire-9 (PHQ-9) Score, general anxiety disorder-7 (GAD-7) score. The safety also be observed.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 201203
- ShuGuang Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria (I) Discharged patients fulfilling the diagnostic criteria of COVID-19 (China Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7); (II) COVID-19 RNA in respiratory specimens or blood specimens of patients is negative (>2 times), assayed by real-time fluorescent polymerase chain reaction test (RT-PCR); (III) Pulmonary CT scans within 7 days showed that there were still unabsorbed inflammation or pulmonary fibrosis in the lungs; (IV) Age 18-70.
Exclusion criteria
- Patients who have undergone lung surgery that affects pulmonary function, such as pulmonary transplantation, pulmonary resection, pulmonary volume reduction, etc;
- Relying on mechanical ventilation to maintain pulmonary function, such as ventilators;
- Combined with chronic pulmonary diseases affecting pulmonary function, such as chronic obstructive pulmonary disease, other known causes of interstitial pulmonary disease;
- Patients with diseases affecting cardiac function, such as pulmonary circulation hypertension, heart failure, peripheral vascular disease, fibromyalgia, and pacemaker installation;
- Patients with severe underlying diseases affecting survival, including uncontroled cardiac, renal, digestive, hematological, neuropsychiatric, immune, metabolic diseases, malignant diseases and severe malnutrition;
- Resting heart rate >120 times/min;
- Systolic blood pressure > 180 mmHg, diastolic blood pressure > 100 mmHg;
- Unstable angina pectoris or myocardial infarction occurring within the last month;
- Severe obesity (BMI > 30 kg/m2);
- Allergic constitution, allergic to the drug components involved in the treatment program;
- Pregnant or breastfeeding women;
- Patients with disabilities who are unable to complete the efficacy evaluation questionnaires;
- Difficult collaborators with poor mental health status, suffering from mental illness, patients without self-control, unable to express clearly;
- Those who are participating in other clinical trials;
- According to the investigator's judgment, patients whose enrollment complications or poor compliance will affect the efficacy and safety evaluation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FZHY Group
usual treatment (respiratory function rehabilitation training + Vitamin C tablets)
|
FZHY, administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.
Other Names:
Vitamin C tablets, administration: 0.2g/time, 3 times/ day, oral;
Other Names:
Health exercise, once a day
|
Placebo Comparator: Placebo Group
usual treatment (respiratory function rehabilitation training + Vitamin C tablets)
|
Vitamin C tablets, administration: 0.2g/time, 3 times/ day, oral;
Other Names:
Health exercise, once a day
Placebo , administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The improvement proportion of pulmonary fibrosis
Time Frame: Week 24
|
Evaluation of pulmonary fibrosis Improvement.
pulmonary fibrosis judged by HRCT score.HRCT images are divided into four grades according to the score, and a reduction of one grade is an improvement.
|
Week 24
|
The improvement of lung function
Time Frame: Week 24
|
FVC, FEV1, FVC/FEV1
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The improvement proportion of pulmonary inflammation
Time Frame: Week 24
|
Evaluation of pulmonary inflammation Improvement
|
Week 24
|
The improvement proportion of clinical symptom
Time Frame: Week 24
|
Discomfort symptoms include dyspnea, cough, exhausted, fatigue, insomnia, sweating, poor appetite, diarrhea, etc., which are common manifestations of patients with COVID-19
|
Week 24
|
Quality of Life-BREF (QOL-BREF)
Time Frame: Week 24
|
This scale can reflect the quality of life of patients to some extent.
|
Week 24
|
Patient Health Questionnaire-9(PHQ-9)
Time Frame: Week 24
|
This scale can reflect the quality of life of patients to some extent.
|
Week 24
|
Generalized anxiety disorder-7(GAD-7)
Time Frame: Week 24
|
This scale can reflect the quality of life of patients to some extent.
|
Week 24
|
The 6-minute walk distance
Time Frame: Week 24
|
Evaluation of Lung Function Improvement
|
Week 24
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Chenghai Liu, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Fibrosis
- COVID-19
- Pulmonary Fibrosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Micronutrients
- Vitamins
- Antioxidants
- Ascorbic Acid
Other Study ID Numbers
- Fzhy-ncp-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Fibrosis Due to COVID-19
-
Montefiore Medical CenterSuspended
-
Bursa Yüksek İhtisas Education and Research HospitalRecruitingPneumonia, Viral | COVID-19 Pneumonia | EGFR AmplificationTurkey
-
University of Southern DenmarkOdense University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark; Hvidovre University Hospital and other collaboratorsRecruitingARDS Due to COVID-19Denmark
-
Duke UniversityCompleted
-
Central Hospital, Nancy, FranceRecruitingRespiratory Compliance | ARDS Due to Disease Caused by SARS Co-V-2 | Sequels of COVIDFrance
-
Gilead SciencesTerminatedLiver Fibrosis Due to NASHUnited States, Canada, France, Italy, Germany, Puerto Rico, Spain, United Kingdom
-
Centre Hospitalier Universitaire DijonCompletedCOVID-19 Severe Pneumonia | Severe Pneumonia Due to Other PathogeneFrance
-
Universidade Estadual de LondrinaUnknownChronic Obstructive Pulmonary Disease | Idiopathic Pulmonary Fibrosis | Asthma ChronicBrazil
-
Mansoura UniversityCompletedPost-COVID-19 Syndrome | Lung FibrosisEgypt
-
Pomeranian Medical University SzczecinRecruitingCOVID-19 PneumoniaPoland
Clinical Trials on Fuzheng Huayu Tablet
-
ShuGuang HospitalHubei Hospital of Traditional Chinese Medicine; Jingmen No.1 People's HospitalCompleted
-
Shanghai University of Traditional Chinese MedicineCompleted
-
ShuGuang HospitalBeijing YouAn Hospital; Beijing Ditan Hospital; Shanghai Zhongshan Hospital; Tongji... and other collaboratorsUnknownLiver Cirrhosis Due to Hepatitis B VirusChina
-
ShuGuang HospitalShanghai Zhongshan Hospital; Ruijin Hospital; Shanghai Public Health Clinical... and other collaboratorsUnknown
-
Tarek HassaneinShanghai Sundise Traditional Chinese Medicine Co., Ltd.CompletedChronic Hepatitis C InfectionUnited States
-
ShuGuang HospitalBeijing YouAn Hospital; Beijing Ditan Hospital; Shanghai Zhongshan Hospital; Tongji... and other collaboratorsUnknownHepatitis B Virus Related CirrhosisChina
-
Guang'anmen Hospital of China Academy of Chinese...UnknownHIV Infections | Acquired Immune Deficiency Syndrome VirusChina
-
Guang'anmen Hospital of China Academy of Chinese...UnknownHIV Infections | Acquired Immune Deficiency Syndrome VirusChina
-
Guangdong Provincial Hospital of Traditional Chinese...Recruiting
-
Guang'anmen Hospital of China Academy of Chinese...UnknownHIV Infections | Acquired Immune Deficiency Syndrome VirusChina